A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF)

被引：0
|
作者：
Andersen, C. [1 ]
Mortensen, N. [1 ]
Vestergaard, H. [2 ]
Bjerrum, O. [3 ]
Klausen, T. [4 ]
Hasselbalch, H. [1 ]
机构：
[1] Roskilde Univ Hosp, Dept Haematol, Roskilde, Denmark
[2] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[3] Copenhagen Univ Hosp, Dept Haematol, Copenhagen, Denmark
[4] Herlev Hosp, Dept Haematol, Herlev, Denmark
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P279
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
    Andersen, Christen L.
    Mortensen, Nana B.
    Klausen, Tobias W.
    Vestergaard, Hanne
    Bjerrum, Ole W.
    Hasselbalch, Hans C.
    HAEMATOLOGICA, 2014, 99 (01)
  • [2] A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
    Andersen, Christen L.
    McMullin, Mary F.
    Ejerblad, Elisabeth
    Zweegman, Sonja
    Harrison, Claire
    Fernandes, Savio
    Bareford, David
    Knapper, Steven
    Samuelsson, Jan
    Loefvenberg, Eva
    Linder, Olle
    Andreasson, Bjorn
    Ahlstrand, Erik
    Jensen, Morten K.
    Bjerrum, Ole W.
    Vestergaard, Hanne
    Larsen, Herdis
    Klausen, Tobias W.
    Mourits-Andersen, Torben
    Hasselbalch, Hans C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (04) : 498 - 508
  • [3] A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Lu, Min
    Li, Timmy
    Petersen, Bruce
    Hochman, Tsivia
    Najfeld, Vesna
    Goldberg, Judith D.
    Hoffman, Ronald
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) : 68 - 75
  • [4] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
  • [5] COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Vargas, P.
    Karpovitch, X.
    Alvarado, M.
    Ovilla, R.
    Agreda, G.
    Guzman, P.
    Solis, J.
    Kassack, J.
    Silva, S.
    Zavala, S.
    Morales, J.
    Herrera, A.
    Reynoso, E.
    Rodriguez, M.
    Ruiz, G.
    Sobrevilla, P.
    Garcia, M.
    Aguilar, C.
    Morales, R.
    Barrera, E.
    Osuna, A.
    Carrillo, R.
    Silos, G.
    Vega, A.
    Cuin, S.
    Mora, M.
    Best, C.
    Murillo, E.
    Loarca, L.
    Perez, O.
    Salazar, J.
    Baez, E.
    Montemayor, J.
    Barrera, D.
    Garcia, J.
    Peraza, L.
    Baltazar, S.
    Iniguez, L.
    Oseguera, R.
    Nacho, K.
    Romero, T.
    HAEMATOLOGICA, 2013, 98 : 765 - 766
  • [6] A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia
    Andersen, Christen Lykkegaard
    McMullin, Mary Frances
    Ejerblad, Elisabeth
    Zweegman, Sonja
    Harrison, Claire N.
    Fernandes, Savio
    Bareford, David
    Knapper, Steven
    Samuelsson, Jan
    Lofvenberg, Eva
    Linder, Olle
    Andreasson, Bjorn
    Ahlstrand, Erik
    Jensen, Morten K.
    Bjerrum, Ole Weis
    Vestergaard, Hanne
    Larsen, Herdis
    Klausen, Tobias Wirenfeldt
    Mourits-Andersen, Torben
    Hasselbalch, Hans
    BLOOD, 2012, 120 (21)
  • [7] An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    Barosi, Giovanni
    Agarwal, Mohan
    Zweegman, Sonja
    Willenbacher, Wolfgang
    Pakstyte, Sima
    Raymakers, Reinier
    Cantoni, Nathan
    Modi, Ankur
    Khan, Mahmudul
    Perez, Jose Ricardo
    Hasselbalch, Hans
    Vargas Viveros, Jose Pablo
    Linardi, Camila C. G.
    Gisslinger, Heinz
    Daumas Gabriel, Adelmo Henrique
    Palandri, Francesca
    Lavie, David
    Harrison, Claire N.
    BLOOD, 2012, 120 (21)
  • [8] The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    McMullin, Mary Frances
    Harrison, Claire N.
    Niederwieser, Dietger
    Demuynck, Hilde
    Jakel, Nadja
    Sirulnik, Andres
    McQuity, Mari
    Stalbovskaya, Viktoriya
    Recher, Christian
    Theunissen, Koen
    Gisslinger, Heinz
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa-Kathrin
    BLOOD, 2012, 120 (21)
  • [9] A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis
    Verstovsek, Srdan
    Savona, Michael R.
    Mesa, Ruben A.
    Dong, Hua
    Maltzman, Julia D.
    Sharma, Shringi
    Silverman, Jeffrey
    Oh, Stephen T.
    Gotlib, Jason
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (06) : 939 - 949
  • [10] Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post - Polycythemia, Vera Myelofibrosis (PPV - MF), and Post Essential Thrombocythemia Myelofibrosis (PET - MF)
    Vargas, Pablo
    Ovilla, Roberto
    Alvarado, Martha
    Lopez, Manuel
    Hurtado Monroy, Rafael
    Carlos Solis, Juan
    Limon, Alejandro
    Agreda, Gladys
    Silva, Salvador
    Julio Kassack, Juan
    Zavala, Saida
    Aguilar, Carlos
    Baez, Enrique
    Barrera, Esperanza
    Osuna, Antonio
    Morales, Javier
    Herrera, Aquileo
    BLOOD, 2012, 120 (21)
12345